ENTRADA THERAPEUTICS, INC.
Entrada Therapeutics, Inc. (ticker TRDA) is a biotechnology company developing technologies aimed at delivering large-molecule therapies into cells. The company's work focuses on enabling intracellular delivery of oligonucleotides, proteins and other biologics — a technical challenge that could broaden the applicability of nucleic‑acid and protein medicines. With a market capitalisation of $241.92M, Entrada's value drivers are likely to include pipeline progress, partnerships and any validation of its delivery platform. Investing in small‑cap biotechs carries higher risk: development timelines can be long, R&D spending is typically substantial, outcomes may be binary and equity dilution is common. This summary is for general educational purposes only and does not constitute financial advice. Consider company filings, cash runway, clinical or regulatory milestones and consult a regulated financial adviser to assess whether TRDA fits your risk profile and investment horizon.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Entrada Therapeutics' stock as it has great potential for growth.
Financial Health
Entrada Therapeutics is generating solid revenue and cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TRDA
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform Potential
A delivery platform could expand which diseases are treatable and create licensing opportunities, though technical and clinical validation remain crucial.
Early-stage Programme
Progress in preclinical or early clinical programmes can be catalytic for valuation, but outcomes are uncertain and timelines can be lengthy.
Partnering & Licensing
Collaborations can de‑risk development and provide funding; however, deal terms, milestones and future financing needs are important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
